AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18803039 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 2474
Study 18803039 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 2474
Study 16845327 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 90
Study 16845327 — intervention group
Group type: COMPARATOR
Intervention: Biochemotherapy
Number of subjects: 90
Study 12627986 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 252
Study 12627986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 10857066 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound (frequency: 1.5 MHz, pulsed by 1 kHz, intensity: 30 mW/cm2, daily 20 minutes treatment)
Number of subjects: 30
Study 10857066 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (casting)
Number of subjects: 30
Study 9165546 — intervention group
Group type: COMPARATOR
Intervention: Standard fixed dose of 500 mg/day of oral zidovudine
Number of subjects: 8
Study 9165546 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentration-controlled regimen of oral zidovudine
Number of subjects: 8
Study 1587194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (mean 2150 mg/day, range 1200-3000 mg/day)
Number of subjects: 12
Study 1587194 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (mean 33 mg/day, range 20-60 mg/day)
Number of subjects: 12
Study 1587194 — intervention group
Group type: COMPARATOR
Intervention: Control (Basal evaluation)
Number of subjects: 12
Study 2422479 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg sulphinpyrazone (SP)
Number of subjects: 60
Study 2422479 — intervention group
Group type: COMPARATOR
Intervention: 880 mg acetylsalicylic acid (ASA)
Number of subjects: 60
Study 2422479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30303707 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate, High-Fat diet with 15-min postmeal walks (LC+Ex)
Number of subjects: 11
Study 30303707 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate, High-Fat diet (LC)
Number of subjects: 11
Study 30303707 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Low-Glycemic Index diet (GL)
Number of subjects: 11
Study 28934966 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive telerehabilitation intervention with home-based exercise training for 3 months
Number of subjects: 110
Study 28934966 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive telerehabilitation intervention
Number of subjects: 110
Study 28934966 — intervention group
Group type: COMPARATOR
Intervention: Usual aftercare programs
Number of subjects: 110
Study 26302250 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 731
Study 26302250 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 731
Study 23709302 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 62
Study 23709302 — intervention group
Group type: COMPARATOR
Intervention: Tramadol
Number of subjects: 62
Study 21955862 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (100 mg/day losartan after 40 mg/d enalapril for 4 months)
Number of subjects: 56
Study 21955862 — intervention group
Group type: COMPARATOR
Intervention: ACEI monotherapy (40 mg/d enalapril for 4 months)
Number of subjects: 56
Study 18439566 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye bank predissected corneal grafts
Number of subjects: 40
Study 18439566 — intervention group
Group type: COMPARATOR
Intervention: Surgeon-dissected corneal grafts
Number of subjects: 40
Study 17319446 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study 17319446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14744276 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose eptifibatide (two 180-microg/kg single-dose boluses before CAS, then a 2.0-microg/kg/min infusion for 20-24 hours)
Number of subjects: 26
Study 14744276 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose eptifibatide
Number of subjects: 26
Study 10653829 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption
Number of subjects: 34
Study 10653829 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (control group)
Number of subjects: 34
Study 9055135 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg valsartan
Number of subjects: 129
Study 9055135 — intervention group
Group type: COMPARATOR
Intervention: 10 mg lisinopril
Number of subjects: 129
Study 9055135 — intervention group
Group type: COMPARATOR
Intervention: 25 mg hydrochlorothiazide
Number of subjects: 129
Study 9055135 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adverse experiences
Number of subjects: 129
Study 8417172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 800 mg daily
Number of subjects: 215
Study 8417172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 600 mg daily
Number of subjects: 215
Study 8417172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 8417172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin 600 mg or 800 mg for 24 weeks
Number of subjects: 215
Study 8417172 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 215
Study 3712027 — intervention group
Group type: EXPERIMENTAL
Intervention: PRGR with trigeminal cisternography (50 cases)
Number of subjects: 100
Study 3712027 — intervention group
Group type: COMPARATOR
Intervention: PRGR without trigeminal cisternography (50 cases)
Number of subjects: 100
Study 31870421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored psychological intervention (access to psychological treatment)
Number of subjects: 0
Study 31870421 — intervention group
Group type: COMPARATOR
Intervention: Control group (waitlist period of 6 months)
Number of subjects: 0
Study 29225442 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith-integrated (FI) intervention
Number of subjects: 372
Study 29225442 — intervention group
Group type: EXPERIMENTAL
Intervention: Secular (SEC) intervention
Number of subjects: 372
Study 29225442 — intervention group
Group type: COMPARATOR
Intervention: Self-guided (SG) control
Number of subjects: 372
Study 25481916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) patches plus behavioral support
Number of subjects: 0
Study 25481916 — intervention group
Group type: COMPARATOR
Intervention: Behavioral support alone
Number of subjects: 0
Study 23708245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cybele(®) Scagel
Number of subjects: 10
Study 23708245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21852030 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA intervention (n = 38)
Number of subjects: 79
Study 21852030 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 41)
Number of subjects: 79
Study 19141765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA enteral feeds (approximately 1% total fatty acids)
Number of subjects: 657
Study 19141765 — intervention group
Group type: COMPARATOR
Intervention: Standard DHA enteral feeds (approximately 0.3% total fatty acids)
Number of subjects: 657
Study 19141765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA diet in girls
Number of subjects: 657
Study 19141765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA diet in infants born weighing less than 1250 g
Number of subjects: 657
Study 19141765 — intervention group
Group type: COMPARATOR
Intervention: Standard DHA in infants born weighing less than 1250 g
Number of subjects: 657
Study 19141765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-DHA diet in infants born weighing at least 1250 g
Number of subjects: 657
Study 19141765 — intervention group
Group type: COMPARATOR
Intervention: Standard DHA in infants born weighing at least 1250 g
Number of subjects: 657
Study 17295822 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual patients intervention group (14 simulated cases of abdominal pain over 7 weeks)
Number of subjects: 48
Study 17295822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to software)
Number of subjects: 48
Study 17295822 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual case exam (from intervention group)
Number of subjects: 48
Study 15483282 — intervention group
Group type: COMPARATOR
Intervention: Reconstituted blood
Number of subjects: 200
Study 15483282 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh whole blood
Number of subjects: 200
Study 11568065 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ultrafiltration after cardiopulmonary bypass
Number of subjects: 573
Study 9722217 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised clinical trials with adequate generation of allocation sequence
Number of subjects: 166
Study 9722217 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised clinical trials with adequate allocation concealment
Number of subjects: 166
Study 9722217 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised clinical trials allowing intention-to-treat analysis
Number of subjects: 166
Study 9722217 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind randomised clinical trials
Number of subjects: 166
Study 9722217 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised clinical trials reporting sample-size calculations
Number of subjects: 166
Study 9722217 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover design trials
Number of subjects: 166
Study 9722217 — intervention group
Group type: EXPERIMENTAL
Intervention: Median number of subjects per intervention arm in parallel group trials
Number of subjects: 166
Study 7920949 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH (Fluorescence In Situ Hybridization)
Number of subjects: 10
Study 7920949 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR (Polymerase Chain Reaction)
Number of subjects: 10
Study 7920949 — intervention group
Group type: EXPERIMENTAL
Intervention: FISH
Number of subjects: 10
Study 2968769 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 0.3 mg (SAL)
Number of subjects: 7
Study 2968769 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Salbutamol 0.3 mg and Disodium Cromoglycate 3 mg (SAL + DSCG)
Number of subjects: 7
Study 2968769 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium Cromoglycate 3 mg (DSCG)
Number of subjects: 7
Study 2968769 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide 80 ug (IB)
Number of subjects: 7
Study 2968769 — intervention group
Group type: COMPARATOR
Intervention: Placebo (peroral lactose pill)
Number of subjects: 7
Study 31683491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-electrode-based transcranial direct current stimulation (tDCS) at 2 mA for 20 minutes
Number of subjects: 60
Study 31683491 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 60
Study 31683491 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry-electrode-based transcranial direct current stimulation (tDCS)
Number of subjects: 60
Study 30914064 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg or 125/25 μg
Number of subjects: 3021
Study 30914064 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium (UMEC) 62.5 μg or 125 μg
Number of subjects: 3021
Study 30914064 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 μg
Number of subjects: 3021
Study 30914064 — intervention group
Group type: EXPERIMENTAL
Intervention: All bronchodilators (UMEC/VI, UMEC, VI)
Number of subjects: 3021
Study 30914064 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/vilanterol (UMEC/VI)
Number of subjects: 3021
Study 30914064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 3021
Study 29126416 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate (Anticholium®) for up to 5 days
Number of subjects: 20
Study 29126416 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (placebo) for up to 5 days
Number of subjects: 20
Study 29126416 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate (Anticholium®)
Number of subjects: 20
Study 29126416 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (placebo)
Number of subjects: 20
Study 26447261 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-based motivational intervention (20-30 minute motivational interview by a masters-prepared social worker and a follow-up reinforcement call)
Number of subjects: 0
Study 26447261 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 0
Study 23336603 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component school-based intervention with a part-time physical activity consultant
Number of subjects: 10
Study 23336603 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 schools not receiving the intervention)
Number of subjects: 10
Study 21931767 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz STN-DBS
Number of subjects: 12
Study 21931767 — intervention group
Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 12
Study 21931767 — intervention group
Group type: COMPARATOR
Intervention: ≥ 130-Hz STN-DBS
Number of subjects: 12
Study 21931767 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 12
Study 21931767 — intervention group
Group type: EXPERIMENTAL
Intervention: Milliseconds timing
Number of subjects: 12
Study 19031126 — intervention group
Group type: EXPERIMENTAL
Intervention: PPH1 group (standard PPH operation)
Number of subjects: 112
Study 19031126 — intervention group
Group type: EXPERIMENTAL
Intervention: PPH2 group (PPH and external hemorrhoids excision)
Number of subjects: 112
Study 19031126 — intervention group
Group type: COMPARATOR
Intervention: Milligan‐Morgan group (Milligan‐Morgan hemorrhoidectomy)
Number of subjects: 112
Study 17070158 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 798
Study 17070158 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 798
Study 12830440 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily HD
Number of subjects: 23
Study 12830440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal HD
Number of subjects: 23
Study 12830440 — intervention group
Group type: COMPARATOR
Intervention: Conventional HD (Control)
Number of subjects: 23
Study 10752810 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamezapine (CBZ) 100 mg every 8 hours
Number of subjects: 12
Study 10752810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10752810 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamezapine (CBZ)
Number of subjects: 12
Study 15328635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative application of 50 mg 5‐FU (Group A)
Number of subjects: 36
Study 15328635 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative subconjunctival injections of 5 mg 5‐FU (Group B)
Number of subjects: 36
Study 15328635 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra and postoperative administration of 5‐FU (Group C)
Number of subjects: 36
Study 8482191 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactitol
Number of subjects: 4
Study 8482191 — intervention group
Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 4
Study 6743990 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-to-side A-V fistula
Number of subjects: 71
Study 6743990 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-side A-V fistula
Number of subjects: 71
Study 6743990 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroperative measurements of fistula flow
Number of subjects: 71
Study 29781394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with Relaxation (CBT + R)
Number of subjects: 180
Study 29781394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with Imagery Rescripting (CBT + ImRs)
Number of subjects: 180
Study 29781394 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderated Self-Help Group (SH)
Number of subjects: 180
Study 28549015 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF) on the first postoperative day
Number of subjects: 280
Study 28549015 — intervention group
Group type: COMPARATOR
Intervention: Late oral feeding (LOF) 7 days after surgery
Number of subjects: 280
Study 28549015 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (EOF)
Number of subjects: 280
Study 28549015 — intervention group
Group type: COMPARATOR
Intervention: Late oral feeding (LOF)
Number of subjects: 280
Study 25997842 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-distancing (third person perspective)
Number of subjects: 96
Study 25997842 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-distancing (exemplar perspective, e.g., Batman)
Number of subjects: 96
Study 25997842 — intervention group
Group type: COMPARATOR
Intervention: Control group (no self-distancing)
Number of subjects: 96
Study 23915290 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years parent training enhanced with home visits
Number of subjects: 133
Study 23915290 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 133
Study 20479444 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraGauze
Number of subjects: 0
Study 20479444 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraGauze + becaplermin
Number of subjects: 0
Study 20479444 — intervention group
Group type: COMPARATOR
Intervention: Saline-moistened gauze + becaplermin (historical data)
Number of subjects: 0
Study 15664716 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/70 kg d-amphetamine
Number of subjects: 22
Study 15664716 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg/70 kg d-amphetamine
Number of subjects: 22
Study 15664716 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/70 kg (placebo)
Number of subjects: 22
Study 11468472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary corticocancellous bone plug (group A)
Number of subjects: 60
Study 11468472 — intervention group
Group type: COMPARATOR
Intervention: Austin Moore hemiarthroplasty alone (group B)
Number of subjects: 60
Study 9710164 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week muscle strength training program of the upper extremities
Number of subjects: 16
Study 7976644 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (mean rate 232 mg/h, range 150‐400 mg/h)
Number of subjects: 15
Study 7976644 — intervention group
Group type: COMPARATOR
Intervention: Morphine (mean rate 2.3 mg/h, range 0‐4 mg/h)
Number of subjects: 15
Study 7976644 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (mean rate 2.8 mg/h, range 0‐5 mg/h)
Number of subjects: 15
Study 2499466 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple insulin injections (MII)
Number of subjects: 20
Study 2499466 — intervention group
Group type: COMPARATOR
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 20
Study 1095246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal beclomethasone dipropionate aerosol (400 mug/day)
Number of subjects: 35
Study 27872387 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cancer worry
Number of subjects: 2154
Study 27872387 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perceived risk
Number of subjects: 2154
Study 27872387 — intervention group
Group type: COMPARATOR
Intervention: Cancer worry
Number of subjects: 2154
Study 28051240 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of montelukast, azithromycin and bronchodilators or glucocorticoid
Number of subjects: 96
Study 28051240 — intervention group
Group type: COMPARATOR
Intervention: Combined therapy using azithromycin and bronchodilators or glucocorticoid
Number of subjects: 96
Study 24579084 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 0
Study 24579084 — intervention group
Group type: COMPARATOR
Intervention: Control (no fish oil)
Number of subjects: 0
Study 24579084 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 0
Study 22718792 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty (DALK)
Number of subjects: 140
Study 22718792 — intervention group
Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 140
Study 20348361 — intervention group
Group type: EXPERIMENTAL
Intervention: Clown intervention (children accompanied by parents and clowns)
Number of subjects: 70
Study 20348361 — intervention group
Group type: COMPARATOR
Intervention: Control (children accompanied by parents without clowns)
Number of subjects: 70
Study 18454213 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia with fentanyl
Number of subjects: 100
Study 18454213 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl
Number of subjects: 100
Study 18454213 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 15837236 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAM2000 (highest dose)
Number of subjects: 0
Study 15837236 — intervention group
Group type: COMPARATOR
Intervention: Dryvax
Number of subjects: 0
Study 15837236 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAM2000 (dilution doses)
Number of subjects: 0
Study 15837236 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAM2000 and Dryvax (adverse events)
Number of subjects: 0
Study 12888057 — intervention group
Group type: EXPERIMENTAL
Intervention: Microkeratome incision followed by laser ablation
Number of subjects: 17
Study 12888057 — intervention group
Group type: COMPARATOR
Intervention: Control eyes (conventional LASIK treatment)
Number of subjects: 17
Study 12888057 — intervention group
Group type: COMPARATOR
Intervention: Both study and control eyes post-laser ablation
Number of subjects: 17
Study 10454950 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas, Metformin, or Insulin
Number of subjects: 0
Study 8730222 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 0
Study 8730222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1829732 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.2%)
Number of subjects: 52
Study 1829732 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous fluoride (0.2%)
Number of subjects: 52